These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2865484)

  • 1. Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform.
    Mannucci PM; Colombo M; Rodeghiero F
    Lancet; 1985 Nov; 2(8462):1013. PubMed ID: 2865484
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.
    Fletcher ML; Trowell JM; Craske J; Pavier K; Rizza CR
    Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1754-7. PubMed ID: 6416577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute fulminant non-A, non-B hepatitis leading to chronic active hepatitis after treatment with cryoprecipitate.
    Lee CA; Kernoff PB; Karayiannis P; Thomas HC
    Gut; 1985 Jun; 26(6):639-41. PubMed ID: 3924749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate.
    Colombo M; Mannucci PM; Carnelli V; Savidge GF; Gazengel C; Schimpf K
    Lancet; 1985 Jul; 2(8445):1-4. PubMed ID: 2861454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-A, non-B hepatitis and heat-treated factor VIII concentrates.
    Preston FE; Hay CR; Dewar MS; Greaves M; Triger DR
    Lancet; 1985 Jul; 2(8448):213. PubMed ID: 2862396
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical studies with treated clotting factor concentrates.
    Colombo M; Mannucci PM
    Dev Biol Stand; 1987; 67():333-6. PubMed ID: 3038639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.
    Hollinger FB; Dolana G; Thomas W; Gyorkey F
    J Infect Dis; 1984 Aug; 150(2):250-62. PubMed ID: 6432922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
    Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate.
    Bergman GE
    Lancet; 1995 Nov; 346(8985):1296-7. PubMed ID: 7475737
    [No Abstract]   [Full Text] [Related]  

  • 11. Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment.
    Rubinstein AI; Rubinstein DB
    Am J Hematol; 1990 Oct; 35(2):142. PubMed ID: 2119141
    [No Abstract]   [Full Text] [Related]  

  • 12. Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of U.K. Haemophilia Centre Directors.
    Rizza CR; Fletcher ML; Kernoff PB
    Br J Haematol; 1993 Jun; 84(2):269-72. PubMed ID: 8398829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate.
    Kessler C; Lusher J; Pierce GF; Pierce B; Koerper MA; Dickinson JC
    Lancet; 1995 Nov; 346(8985):1297-8. PubMed ID: 7475738
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate.
    Berntorp E; Nilsson IM; Ljung R; Widell A
    Lancet; 1990 Jun; 335(8704):1531-2. PubMed ID: 1972463
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 16. Wet heating for safer factor VIII concentrate?
    Kernoff PB; Miller EJ; Savidge GF; Machin SJ; Dewar MS; Preston FE
    Lancet; 1985 Sep; 2(8457):721. PubMed ID: 2863697
    [No Abstract]   [Full Text] [Related]  

  • 17. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.
    Skidmore SJ; Pasi KJ; Mawson SJ; Williams MD; Hill FG
    J Med Virol; 1990 Jan; 30(1):50-2. PubMed ID: 2106006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttransfusion non-A, non-B hepatitis: physicochemical properties of two distinct agents.
    Bradley DW; Maynard JE; Popper H; Cook EH; Ebert JW; McCaustland KA; Schable CA; Fields HA
    J Infect Dis; 1983 Aug; 148(2):254-65. PubMed ID: 6411832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 20. Heat-treated NHS factor VIII concentrate in the United Kingdom--a preliminary study.
    Colvin BT; Ainsworth M; Machin SJ; Mackie IJ; Smith JK; Winkelman L; Haddon ME
    Clin Lab Haematol; 1986; 8(2):85-92. PubMed ID: 3015481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.